Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1937653 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $22.71Day +3.18%Mkt cap $1.7B1Y +75.5%Off 52W high −23.7%Vol (1Y) 54.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,320 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.6% of sh out |
| Days to cover7.6d |
| 13F net flow (QoQ)+3.16% |
| Top-10 13F concentration71.4% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$81.3M |
| Earnings (TTM)-$102.7M |
| ROE−26.7% |
| Net margin−76.6% |
| ROIC−29.2% |
| Sales growth 3Y−36.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−13.7% |
| 1Y+75.5% |
| 3Y+204.4% |
| 5Y−29.2% |
| Since incept. (ann.)+6.2% |
Total return through 2026-07-30 · series begins 2017-04-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)54.0% |
| Ann. volatility (3Y)49.2% |
| Sharpe (1Y)1.24 |
| Sharpe (3Y)1.01 |
| Max drawdown (1Y)−22.9% |
| Max drawdown (3Y)−45.7% |
| Beta (3Y vs SPY)0.95 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 23.0M | $575M | 31.15% | +0.0% |
| Rubric Capital Management LP | 7.0M | $175M | 9.49% | +21.7% |
| BlackRock, Inc. | 4.6M | $114M | 6.17% | −0.9% |
| BVF INC/IL | 3.7M | $94M | 5.06% | −5.2% |
| PERCEPTIVE ADVISORS LLC | 3.5M | $88M | 4.76% | +7.6% |
| MORGAN STANLEY | 2.5M | $62M | 3.36% | −4.3% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.9M | $48M | 2.59% | +4.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $43M | 2.31% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.59 | — | $2.4M | −91.1% |
| 2025-12-31 | 2026-03-02 | — | — | $2.5M | −91.9% |
| 2025-09-30 | 2025-11-06 | −$0.26 | — | $27.6M | +72.6% |
| 2025-06-30 | 2025-08-07 | $0.03 | — | $48.7M | +153.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
